ICD-10 I74.2 is officially defined as "Embolism and thrombosis of arteries of the upper extremities." code I74.2 is referenced in 5 tracked payer policy changes from UnitedHealthcare and Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code I74.2 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
UnitedHealthcare's Medicare Advantage ambulatory electrocardiographic (AECG) monitoring policy was revised effective September 1, 2026, which has already passed. It adds a long list of ICD-10 diagnosis codes for the AECG CPT codes, revises coverage where no CMS local coverage determination exists, and says AECG monitoring with an FDA-cleared device is reasonable and necessary for arrhythmia monitoring before and after TAVR.
Aetna considers electrical stimulation medically necessary durable medical equipment for arterial ulcers, diabetic ulcers, Stage III or IV pressure ulcers, and venous stasis ulcers when it is used as adjunctive therapy after no measurable signs of healing for at least 30 days of conventional wound treatment. Courses exceeding 1 hour per day are not considered medically necessary, continued stimulation is not medically necessary if measurable healing is not shown within a 4-week treatment period or once the wound bed is 100% epithelialized, and electrical stimulation for chronic ulcers in the home setting is considered not medically appropriate. Aetna considers electrical stimulation experimental, investigational, or unproven for uses including prevention of ulcers and pressure sores, infected wounds, microcurrent as an adjunctive therapy, and the VeinoPlus device for venous ulcers.
Aetna considers full-leg or half-leg home-use pneumatic compression devices medically necessary durable medical equipment for chronic venous insufficiency of the legs in members with venous stasis ulcers that have failed to heal after a 6-month trial of conservative therapy directed by the treating physician. Intermittent pneumatic compression devices for the lower extremities are considered medically necessary for members who are bedridden due to trauma, orthopedic surgery, neurosurgery or other circumstances preventing ambulation, and a single patient use device is considered not medically necessary. Aetna lists other uses as experimental, investigational or unproven, including treatment of critical limb ischemia, intermittent claudication, post-thrombotic syndrome, restless legs syndrome and intra-operative compression for reduction of venous thromboembolism in craniotomy.
Aetna's Clinical Policy Bulletin 0814 considers remote ischemic conditioning experimental, investigational, or unproven for many indications because its effectiveness has not been established. The listed indications include acute coronary syndromes in individuals undergoing percutaneous coronary intervention, prevention of contrast-induced acute kidney injury, improvement of outcomes in individuals with acute ischemic stroke undergoing intravenous thrombolysis, improvement of outcomes following orthopedic surgery, sepsis management, and treatment of ulcerative colitis. The bulletin states that there are no specific codes for remote ischemic conditioning.
Aetna considers electrical stimulation for chronic ulcers medically necessary durable medical equipment for arterial ulcers, diabetic ulcers, Stage III or IV pressure ulcers, and venous stasis ulcers when it is used as adjunctive therapy after there are no measurable signs of healing for at least 30 days of conventional wound treatment. A course of treatment is not typically expected to exceed 60 minutes per day or a total of more than 4 weeks, and continued stimulation is not medically necessary if measurable signs of healing are not demonstrated within a 4-week treatment period. Electrical stimulation for chronic ulcers in the home setting is considered not medically appropriate, and it is considered experimental, investigational, or unproven for uses such as prevention of ulcers and pressure sores, treatment of infected wounds, and microcurrent as an adjunctive therapy to enhance chronic wound healing.
Watch I74.2
Get one email when a payer policy names I74.2, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.